{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06293898",
            "orgStudyIdInfo": {
                "id": "BL-M07D1-ST-101"
            },
            "organization": {
                "fullName": "SystImmune Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors",
            "officialTitle": "A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "open-label-study-to-evaluate-bl-in-expressing-malignant-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08-24",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-08-24",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-22",
            "studyFirstSubmitQcDate": "2024-03-01",
            "studyFirstPostDateStruct": {
                "date": "2024-03-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "SystImmune Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.",
            "detailedDescription": "BL-M07D1-ST-101 is a global, multi-center, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M07D1 in participants with HER2 expressing advanced malignant solid tumors.\n\nThis study will be conducted in three parts (dose escalation, dose finding and dose expansion). Dosing will be conducted on Day 1 of a continuous 21-day treatment cycle. ."
        },
        "conditionsModule": {
            "conditions": [
                "Endometrial Cancer",
                "Cervical Cancer",
                "Ovarian Cancer",
                "Urothelial Carcinoma",
                "Biliary Tract Cancer",
                "Breast Cancer",
                "Lung Cancer",
                "Gastric Cancer",
                "Gastroesophageal-junction Cancer",
                "Esophageal Cancer"
            ],
            "keywords": [
                "HER2"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 280,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "BL-M07D1 administered Day 1 of a 21-day cycle",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BL-M07D1"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BL-M07D1",
                    "description": "Drug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized.",
                    "armGroupLabels": [
                        "BL-M07D1 administered Day 1 of a 21-day cycle"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Summary of safety",
                    "description": "The number of patients with dose-limiting toxicities, serious adverse events, treatment-emergent adverse events, physical exam findings, vital signs, laboratory tests, ECG parameters and echocardiograph",
                    "timeFrame": "Though study completion, an average of 24 months"
                },
                {
                    "measure": "To determine the maximum tolerated dose (MTD) if reached or maximum administered dose (MAD) and two or more recommended doses for dose expansion (RDEs) of BL-M07D1",
                    "description": "Determine the highest BL-M07D1 dose level at which subjects do not experience a DLT during the DLT evaluation period and highest BL-M07D1 dose administered in the event and MTD cannot be defined.",
                    "timeFrame": "21 Days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age: \u226518 years\n2. Has a life expectancy of \u22653 months\n3. Has documented locally advanced or metastatic HER2-expressing (IHC 1+ to 3+ and/or HER2 gene amplification in tumor specimen or in circulating tumor cells by ISH, NGS, or ctDNA-NGS) solid tumor(s) not amenable to curative surgery or radiation and has received at least 2 lines of standard therapy, including adjuvant/neoadjuvant treatment, with documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease and have progressed or refractory to standard of care, including:\n\n   1. Cohort 1: Subjects with HER2 expression in endometrial cancers (EC)\n   2. Cohort 2: Subjects with HER2 expression in cervical cancers (CC)\n   3. Cohort 3: Subjects with HER2 expression in ovarian cancers (OC)\n   4. Cohort 4: Subjects with HER2 expression in urothelial cancers (UC)\n   5. Cohort 5: Subjects with HER2 expression in biliary tract cancers (BTC)\n   6. Cohort 6: Subjects with HER2 expression in breast cancer (BC)\n   7. Cohort 7: Subjects with HER2 expression in lung cancer (LC)\n   8. Cohort 8: Subjects with HER2 expression in gastric, esophageal, or gastroesophageal junction (GEJ) cancers\n4. Agree to provide existing tumor samples\n5. Has at least one measurable lesion based on RECIST (Response Evaluation Criteria in Solid Tumors) V1.1\n6. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1\n7. Toxicity of previous antitumor therapy has returned to Grade \u22641\n8. Has no serious cardiac dysfunction, left ventricular ejection fraction \u226550%\n9. Has adequate organ function before registration\n10. Coagulation function: international normalized ratio (INR) \u22641.5\u00d7ULN, and activated partial thromboplastin time (APTT) \u22641.5 ULN\n11. Urinary protein \u22642+ or \u22641000 mg/24 hours\n12. For premenopausal women with childbearing potential, a pregnancy test must be taken within 7 days prior to the start of treatment. Serum or urine pregnancy test must be negative and subject must be nonlactating.\n13. Must agree to use adequate contraceptive measures during the treatment and for 6 months after the end of treatment for all subjects (regardless of gender)\n\nExclusion Criteria:\n\n1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other antitumor therapy within 2 weeks or 5 half-lives (whichever is shorter) prior to the first administration; major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration\n2. Subjects with history of severe heart disease\n3. Subjects with prolonged QT interval (QTc \\>470 msec), complete left bundle branch block, Grade 3 atrioventricular block\n4. Active autoimmune diseases and inflammatory diseases\n5. Other malignant tumors diagnosed within 5 years prior to the first administration considered to be in remission\n6. Subjects with poorly controlled hypertension by two kinds of antihypertensive drugs (systolic blood pressure \\>150 mmHg or diastolic blood pressure \\>100 mmHg)\n7. Subjects who have Grade 3 lung disease or a history of interstitial lung disease\n8. Deep vein thrombosis or pulmonary embolism unless under adequate anticoagulant treatment\n9. Patients with primary tumors in the central nervous system (CNS) and active or untreated CNS metastases and/or carcinomatous meningitis should be excluded. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks and have no evidence of new or enlarging brain metastases and no requirements for corticosteroids 14 days prior to dosing with the investigational product (IP). Patients on low dose corticosteroids (\\<20 mg prednisone or equivalent/day) may participate.\n10. Subjects who have a history of allergies to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL M07D1\n11. Subjects who have a history of autologous or allogeneic stem cell transplantation\n12. Has received treatment with anthracyclines with a cumulative dose exceeding 360 mg/m2\n13. Known human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number \\> the lower limit of detection) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA \\> the lower limit of detection)\n14. Subjects with active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.\n15. Participated in another clinical trial within 4 weeks or two half-lives (whichever is longer) prior to first dose of study treatment\n16. Other conditions that the investigator believes are not suitable for participating in this clinical trial.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Tara Barrineau",
                    "role": "CONTACT",
                    "phone": "4254536841",
                    "email": "tara.barrineau@systimmune.com"
                },
                {
                    "name": "Whitney Eakins",
                    "role": "CONTACT",
                    "phone": "4254536841",
                    "email": "whitney.eakins@systimmune.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Leader",
                    "affiliation": "SystImmune Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "SystImmune Recruiting Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10469",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "SystImmune Recruiting Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "11042",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "SystImmune Recruiting Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "11967",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "SystImmune Recruiting Center",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "SystImmune",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "SystImmune Recruiting Center",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000016889",
                    "term": "Endometrial Neoplasms"
                },
                {
                    "id": "D000001661",
                    "term": "Biliary Tract Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                },
                {
                    "id": "D000001660",
                    "term": "Biliary Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5551",
                    "name": "Carcinoma, Transitional Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M8088",
                    "name": "Esophageal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M19235",
                    "name": "Endometrial Neoplasms",
                    "asFound": "Endometrial Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4947",
                    "name": "Biliary Tract Neoplasms",
                    "asFound": "Biliary Tract Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4946",
                    "name": "Biliary Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5693",
                    "name": "Transitional Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T2141",
                    "name": "Esophageal Cancer",
                    "asFound": "Esophageal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T761",
                    "name": "Biliary Tract Cancer",
                    "asFound": "Biliary Tract Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}